Skip to main content
SpringerLink
Log in

Medical and Surgical Therapy for Gastric Cancer

  • Chapter
Endoscopic Oncology

  • 848 Accesses

Abstract

Gastric cancer remains among the 10 most common cancers in the world with variations in incidence and survival based on geographic sites. Gastric cancer is the second most common tumor worldwide with 60% of cases in developing countries (1). It appears that, worldwide, gastric cancer is second only to lung cancer with a reported 798,300 new cases in 1990 and is more common than, breast and colorectal cancer outside of the United States. The highest incidences are in Japanese men; rates are also increased in eastern Europe, South America, and eastern Asia, but lower in the United States, North Africa, and Australia (1). In contrast, esophageal cancer is relatively rare, being the seventh leading cause of death in men in the United States (2). Survival is poor, being only 37% for stage II, 11–18% for stage III, and 5% for stage IV. The effectiveness of surgery, chemotherapy, radiation therapy or the combination of the above modalities has been investigated for decades with varied results.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Parkin DM. Epidemiology of cancer global patterns and trends. Toxicol Lett 1998; 102103:227–234.

    Article  PubMed  Google Scholar 

  2. Ilson DH. Oesophageal cancer: new developments in systemic therapy. Cancer Treatment Rev 2003; 29:525–532.

    Article  Google Scholar 

  3. Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer epidemiology of an unplanned triumph. Epidemiol Rev 1986; 8:1–27.

    PubMed  CAS  Google Scholar 

  4. Correa P. The epidemiology of gastric cancer. World J Surg 1991; 15:228–234.

    Article  PubMed  CAS  Google Scholar 

  5. Dijkhuizen SM, et al. Multiple hyperplastic polyps in the stomach: evidence for clonality and neoplastic potential. Gastroenterology 1997; 112:561,562.

    Article  PubMed  CAS  Google Scholar 

  6. Shiao YH, et al. Implications of p53 mutation spectrum for cancer etiology in gastric cancers of various histologic types from a highrisk area of central Italy. Carcinogenesis 1998; 10:2145–2149.

    Article  Google Scholar 

  7. Correa P, Shiao YH. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 1994; 54:1941s–1943s.

    PubMed  CAS  Google Scholar 

  8. Gong C, et al. KRAS mutations predict progression of preneoplastic gastric lesions. Cancer Epidemiol Biomarkers Prev 1999; 8:167–171.

    PubMed  CAS  Google Scholar 

  9. Hongyo T, et al. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res 1995; 55:2665–2672.

    PubMed  CAS  Google Scholar 

  10. Fedriga R, et al. Relation between food habits and p53 mutational spectrum in gastric cancer patients. Int J Oncol 2000; 17:127–133.

    PubMed  CAS  Google Scholar 

  11. Strickler JG, et al. P53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res 1994; 54:4750–4755.

    PubMed  CAS  Google Scholar 

  12. Chong JM, et al. Microsatelllite instability in the progression of gastric carcinoma. Cancer Res 1994; 54:4595–4597.

    PubMed  CAS  Google Scholar 

  13. Kobayashi K, et al. Genetic instability in intestinal metaplasia is a frequent event leading to well-differentiated early adenocarcinoma of the stomach. Eur J Cancer 2000; 36:1113–1119.

    Article  PubMed  CAS  Google Scholar 

  14. Palli D, et al. Red meat, family history, and increased risk of gastric cancer with microsatellite instability. Cancer Res 2001; 61:5415–5419.

    PubMed  CAS  Google Scholar 

  15. Lin KM, et al. Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J Gastrointest Surg 1998; 2:67–71.

    Article  PubMed  CAS  Google Scholar 

  16. Vasen HF, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110:1020–1027.

    Article  PubMed  CAS  Google Scholar 

  17. Akiyama Y, et al. Frequent microsatellite instabilities and analyses of the related genes in familial gastric cancers. Jpn J Cancer Res 1996; 87:595–601.

    PubMed  CAS  Google Scholar 

  18. Yanagisawa Y, et al. Methylation of the hMLH1 promoter in familial gastric cancer with microsatelllite instability. Int J Cancer 2000; 85:50–53.

    Article  PubMed  CAS  Google Scholar 

  19. Keller G, et al. Microsatellite instability and loss of heterozygosity in gastric carcinoma in comparison to family history. Am J Pathol 1998; 152:1281–1289.

    PubMed  CAS  Google Scholar 

  20. Enomoto M, et al. The relationship between frequencies of extracolonic manifestations and the position of APC germline mutation in patients with familial adenomatous polyposis. Jpn J Clin Oncol 2000; 30:82–88.

    Article  PubMed  CAS  Google Scholar 

  21. Shinmura K, et al. Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutaiton. Carcinogenesis 199; 20:1127–1131.

    Google Scholar 

  22. Varley JM, et al. An extended li-Fraumeni kindred with gastric carcinoma and a codon 175 mutation in PT53. J Med Genet 1995; 32:942–945.

    PubMed  CAS  Google Scholar 

  23. Sugano K, et al. Germline p53 mutaiton in a case of Li-Fraumeni syndrome presenting as gastric cancer. Jpn J Clin Oncol 1999; 29:513–516.

    Article  PubMed  CAS  Google Scholar 

  24. Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol 1996; 23:281–291.

    PubMed  CAS  Google Scholar 

  25. Chyou PH, et al. A case-cohort study of diet and stomach cancer. Cancer Res 1990; 50:7501–7504.

    PubMed  CAS  Google Scholar 

  26. Blot WJ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Institute 1993; 85:1483–1492.

    Article  CAS  Google Scholar 

  27. Benner SE, Hong Wk. Clinical chemoprevention: developing a cancer prevention strategy. J Natl Cancer Inst 1993; 85:1446–1447.

    Article  PubMed  CAS  Google Scholar 

  28. Chow WH, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998; 90:150–155.

    Article  PubMed  CAS  Google Scholar 

  29. Gammon MD, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1997; 89:1277–1284.

    Article  PubMed  CAS  Google Scholar 

  30. Zhang ZF, Kurtz RC, Marshall JR. Cigarette smoking and esophageal and gastric cardia adenocarcinoma. J Natl Cancer Inst 1997; 89:1247–1249.

    Article  PubMed  CAS  Google Scholar 

  31. Ernst P. Review article: the role of inflammation in the pathogenesis of gastric cancer. Aliment Pharmacol Ther 1999; 13:13–18.

    Article  PubMed  Google Scholar 

  32. Graham DY. Helicobacter pyylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterolgy 1997; 113:1983–1991.

    Article  CAS  Google Scholar 

  33. Danesh J. Helicobacter pylori and gastric cancer: time for megatrials? Br J Cancer 1999; 80:927–929.

    Article  PubMed  CAS  Google Scholar 

  34. Parsonnet J, et al. Risk for gastric cancer in people with CagA positiveor CagA negative Helicobacter pylori infeciton. Gut 1997; 40:297–301.

    PubMed  CAS  Google Scholar 

  35. Blaser MJ, et al. Infection with Helicobacter pylori strains possessing cag A is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995; 55:2111–2115.

    PubMed  CAS  Google Scholar 

  36. Deguchi R, et al. Association between CagA + Helicobacter pylori infection and p53, bax and transforming growth factor-beta-RII gene mutations in gastric cancer patients. Int J Cancer 2001; 91:481–485.

    Article  PubMed  CAS  Google Scholar 

  37. Oota K, Sobin LH. Histological typing of gastric and oesophageal tumors in international histological classification of tumors, WHO, Editor. 1977, WHO: Geneva.

    Google Scholar 

  38. Maehara Y, et al. Prognostic value of p53 expression for patients with gastric cancer-a multivariate analysis. Br J Cancer 1999; 79:1255–1261.

    Article  PubMed  CAS  Google Scholar 

  39. Fonseca L, et al. P53 detection as a prognostic factor in early gastric cancer. Oncology 1994; 51:485–490.

    Article  PubMed  CAS  Google Scholar 

  40. Aizawa K, et al. Apoptosis and bcl-2 expression in gastric cartcinomas: correlation with clnicopathological variables, p53 expression, cell proliferation and prognosis. Int J Oncol 1999; 14:85–91.

    PubMed  CAS  Google Scholar 

  41. Wu CW, et al. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis lymph node metastatsis and poorly differentiated nuclear grade. Br J Cancer 1999; 79:1255–1261.

    Article  Google Scholar 

  42. Maeda K, et al. Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology 1998; 55:594–599.

    Article  PubMed  CAS  Google Scholar 

  43. Martin HM, et al. P53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50:859–862.

    Article  PubMed  CAS  Google Scholar 

  44. Polkowski W, et al. Prognostic value of Lauren classification and cerbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastro-esophageal junction. Ann Surg Oncol 1999; 6:290–297.

    Article  PubMed  CAS  Google Scholar 

  45. Nakajtma M, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1000; 85:1894–1902.

    Google Scholar 

  46. Heiss MM, et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995; 13:2084–2093.

    PubMed  CAS  Google Scholar 

  47. Heiss MM, et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995; 1:1035–1039.

    Article  PubMed  CAS  Google Scholar 

  48. Yonemura Y, et al. Prediction of lymph node metastasis and prognosis from the assay of the expresison of porliferating cell nuclear antigen and DNA ploidy in gastric cancer. Oncology 1994; 51:251–257.

    PubMed  CAS  Google Scholar 

  49. Muller W, et al. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J Pathol 1997; 183:222–227.

    Article  PubMed  CAS  Google Scholar 

  50. Yoo CH, et al. Prognostic significance of CD44 and nm23 expression in patients with stage Ii and stage IIIA gastric carcinoma. J Surg Oncol 1999; 71:22–28.

    Article  PubMed  CAS  Google Scholar 

  51. Hundahl SA, et al. The National Cancer Data Base report on gastric carcinoma. Cancer 1997; 80:2233–2241.

    Article  Google Scholar 

  52. Nakamura K, et al. Pathology and prognosis of gastric carcinoma. Findings in 10000 patientes who underwent primary gastrectomy. Cancer 1992; 70:1030–1037.

    Article  PubMed  CAS  Google Scholar 

  53. Fuchs CS, Mayer RJ. Gastric carcinoma. New Engl J Med 1995; 333:32–41.

    Article  PubMed  CAS  Google Scholar 

  54. Gouzi JL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prosepctive controlled study. Ann Surg 1989; 209:162–166.

    Article  PubMed  CAS  Google Scholar 

  55. Italian Gastrointestinal Tumor Study Group, Bozzetti F, et al. Subtotal versus total gastrectomy for gastric cancer five-year survival rates in a multicenter randomized Italian trial. Ann Surg 1000; 230:170–178.

    Google Scholar 

  56. Roukos DH, Kappas AM, Encke A. Extensive lymph-node dissection in gastric cancer is it of therapeutic value. Cancer Treat Rev 1996; 22:247–252.

    Article  PubMed  CAS  Google Scholar 

  57. Roukos DH. Extended lymphadenectomy in gastric cancer when, for whom and why. Ann R Colll Surg Engl 1998; 80:16–24.

    CAS  Google Scholar 

  58. Jessup JM. Is bigger better. J Clin Oncol 1995; 13:5–7.

    PubMed  CAS  Google Scholar 

  59. Lawrence W, Jr, Horsley JS. Extended lymph node dissections for gastric cancer-is more better? (editorial). J Surg Oncol 1996; 61:85–89.

    Article  PubMed  Google Scholar 

  60. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988; 75:110–112.

    Article  PubMed  CAS  Google Scholar 

  61. Robertson CS, et al. A prospective randomized trial comparing P1 subtotal gastrectomy with R3 total gastrectomy for antral cancer (see comments). Ann Surg 1994; 220:176–182.

    Article  PubMed  CAS  Google Scholar 

  62. Dutch Gastric Cancer Group, Bonenekamp JJ, et al. Extended lymph-node dissection for gastric cancer. New Engl J Med 1999; 340:908–914.

    Article  Google Scholar 

  63. Bonenkamp JJ, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345:745–748.

    Article  PubMed  CAS  Google Scholar 

  64. Surgical Cooperative Group, Cushieri A, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999; 79:1522–1530.

    Article  Google Scholar 

  65. The Surgical Cooperative Group, Cuchieri A, et al. Post-operative morbidity and mortality after D1 and D2 resections for gastric cancer preliminary results of the RMC randomised controlled surgical trial. Lancet 1996; 347:995–999.

    Article  Google Scholar 

  66. Maruyama K, et al. Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995; 19:532–536.

    Article  PubMed  CAS  Google Scholar 

  67. Jentschura D, et al. Surgery for early gastric cancer, a European one-center experience. World J Surg 1997; 21:845–848.

    Article  PubMed  CAS  Google Scholar 

  68. Iriyama K, et al. Is extensive lymphadenectomy necessary for surgical treatment of intramucosal carcinoma of the stomach. Arch Surg 1989; 124:309–311.

    PubMed  CAS  Google Scholar 

  69. Hanazaki K, et al. Clinicopathologic features of submucosal carcinoma of the stomach. J Clin Gastroenterol 1997; 24:150–155.

    Article  PubMed  CAS  Google Scholar 

  70. Hanazaki K, et al. Surgical outcome in early gastric cancer with lymph node metastasis. Hepatogastroenterology 1997; 44:907–911.

    PubMed  CAS  Google Scholar 

  71. Yanai H, et al. Diagnostic utility of 20-megahertz linear endoscopic ultrasonography in early gastric cancer. Gastrointest Endosc 1996; 44:29–33.

    Article  PubMed  CAS  Google Scholar 

  72. Akahoshi K, et al. Pre-operative TN staging of gastric cancer using a 15 MHz ultrasound miniprobe. Br J Radiol 1997; 70:703–707.

    PubMed  CAS  Google Scholar 

  73. Akahoshi K, et al. Endoscopic ultrasonography: a promising method for assessing the prospects of endoscopic mucosal resection in early gastric cancer. Endoscopy 1997; 29:614–619.

    Article  PubMed  CAS  Google Scholar 

  74. Takeshita K, et al. Rational lymphadenectomy for early gastric cancer with submucosal invasion: a clinicopathological study. Surg Today 1998; 28:580–586.

    Article  PubMed  CAS  Google Scholar 

  75. Sano T, Kobori O, Muto T. Lymph node metastatsis from early gastric cancer: endoscopic resection of tumour. Br J Surg 1992; 79:241–244.

    Article  PubMed  CAS  Google Scholar 

  76. Roth AD. Curative treatment of gastric cancer: towards a multidisciplinary approach? Critical Rev in Oncology Hematology. 2003; 46:59–100.

    Article  Google Scholar 

  77. Macdonald JS, et al. 5-fluorouracil, adriamycin and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 1979; 44:42–47.

    Article  PubMed  CAS  Google Scholar 

  78. Cunningham D, et al. Advanced gastric cancer experience in Scotland using 5-fluorouracil adriamycin and mitomycin-C. Br J Surg 1984; 71:673–676.

    Article  PubMed  CAS  Google Scholar 

  79. Haim N, et al. Treatment of advanced gastric carcinoma with 5-fluorouracil adriamycin and mitomycin C (FAM). Cancer Chemother Pharmacol 1982; 8:277–280.

    Article  PubMed  CAS  Google Scholar 

  80. Haim N, et al. Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin) and mitomycin C (modified FAM). Cancer 1984; 54:1999–2002.

    Article  PubMed  CAS  Google Scholar 

  81. Macdonald JS, Gohmann JJ. Chemotherapy of advanced gastric cancer: present status, future prospects. Semin Oncol 1988; 15:42–49.

    PubMed  CAS  Google Scholar 

  82. Wils JA, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-A step ahead in the treatment of advanced gastric cancer. A trial of the Euopean Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9:827–831.

    PubMed  CAS  Google Scholar 

  83. North Central Cancer Treatment Group, Cullinan SA, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994; 12:412–416.

    PubMed  CAS  Google Scholar 

  84. Wils J, et al. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 1986; 4:1799–1803.

    PubMed  CAS  Google Scholar 

  85. Murad Am, et al. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37–41.

    Article  PubMed  CAS  Google Scholar 

  86. Leichman L, Berry BT. Cisplatin therapy for adenocarcinoma fo the stomach. Semin Oncol 1991; 18(Suppl 3):25–33.

    PubMed  CAS  Google Scholar 

  87. Wilke H, et al/ Preoperative chmeotherapy in locally advanced and nonresectable gastric cancer: a phase n study with etoposide, doxorubicin and cisplatin. J Clin Oncol 1989; 7:1318–1326.

    PubMed  CAS  Google Scholar 

  88. Wilke H, et al. Etoposide, folinic acid and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. Cancer Chemother Pharmacol 1991; 29:83–84.

    Article  PubMed  CAS  Google Scholar 

  89. Ychou M, et al. A phase n study of 5-fluorouracil, leucovorin and cisplaitn (FLP) for metastatic gastric cancer. Eur J Cancer 1996; 32A:1933–1937.

    Article  PubMed  CAS  Google Scholar 

  90. Preusser P, Wilke H, Achterrath W. Phase n study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric carcinoma. J Clin Oncol 1989; 7:1310–1317.

    PubMed  CAS  Google Scholar 

  91. Cocconi G, et al. Fluorouracil, doxorubicin and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1994; 12:2687–2693.

    PubMed  CAS  Google Scholar 

  92. Kim NK, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and motomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71:3813–3818.

    Article  PubMed  CAS  Google Scholar 

  93. Kelsen D, et al. FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10:541–548.

    PubMed  CAS  Google Scholar 

  94. Vanhoefer U, et al. Final results of a randomized phsae III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin versus etoposide, leuocovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cacner Cooperative Group. J Clin Oncol 2000; 11:301–306.

    Google Scholar 

  95. Lokich JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carinaoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7:425–432.

    PubMed  CAS  Google Scholar 

  96. Findlay M, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatinin combination with continuousinfusion 5-fluorouracil (ECF). Ann Oncol 1994; 5:609–6616.

    PubMed  CAS  Google Scholar 

  97. Bamias A, et al. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality oflife and survival. Cancer 1996; 77:1978–1985.

    Article  PubMed  CAS  Google Scholar 

  98. Zaniboni A, et al. Epirubicin, cisplatin and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer 1995; 76:1694–1699.

    Article  PubMed  CAS  Google Scholar 

  99. Webb A, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15:261–267.

    PubMed  CAS  Google Scholar 

  100. Cascinu S, et al. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione and filgrastim: A report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 1997; 15:3313–3319.

    PubMed  CAS  Google Scholar 

  101. Chi KH, et al. Weekly etoposide, epirubicin, cisplatin 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer. Br J Cancer 1998; 77:1984–1988.

    PubMed  CAS  Google Scholar 

  102. Schiff PB, Horwitz SB. Taol assembles tubulin in the absence of exogenous guanosine 5′triphosphate or microtubule-associated proteins. Biochemistry 1981; 20:3247–3252.

    Article  PubMed  CAS  Google Scholar 

  103. Einzig AI, et al. Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestintal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results. Invest New Drugs 1995; 13:223–227.

    Article  PubMed  CAS  Google Scholar 

  104. Ajani JA, et al. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998; 4:269–275.

    PubMed  CAS  Google Scholar 

  105. Ohtsu A, et al. An early phase II study of a 3 h infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998; 21:416–419.

    Article  PubMed  CAS  Google Scholar 

  106. Cascinu S, et al. A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. Eur J Cancer 1997; 33:1699–1702.

    Article  PubMed  CAS  Google Scholar 

  107. Bokemeyer C, et al. A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 1997; 8:396–399.

    Article  PubMed  CAS  Google Scholar 

  108. Chun H, et al. Chemotherapy (CT) with cisplatin, fluorouracil (FU) and paclitaxel for adenocarcinoma (AC) of the stomach and gastro-esophageal junction (GEJ). ASCO Proc 1999; 18:280a.

    Google Scholar 

  109. Kim YH, et al. Paclitaxel, 5-fluorouracil and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 1999; 85:295–301.

    Article  PubMed  CAS  Google Scholar 

  110. Lokich JJ, et al. Combined paclitaxel, cisplatin and etoposide for patients with previously untreated esophageal and gastro-esophageal carcinomas. Cancer 1999; 85:2347–2351.

    Article  PubMed  CAS  Google Scholar 

  111. Einzig AI, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of tehupper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996; 13:87–93.

    PubMed  CAS  Google Scholar 

  112. EORTC Early Clinical Trials Group, Sulkes A, et al. Docetaxel (Taxotere) in advanced gastric cancer, results of a Phase II clinical trial. Br J Cancer 1994; 70:380–383.

    PubMed  CAS  Google Scholar 

  113. Mai M, et al. A late phase n clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer; a cooperative study group grial (group B). Gan To Kagaku Ryoho 1999; 26:487–496.

    PubMed  CAS  Google Scholar 

  114. Verweij J, Clavel M, Chevalier B. Paclitaxel(Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994;5:495–505.

    PubMed  CAS  Google Scholar 

  115. Roth AD, et al. Docetaxel (taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK) and the European Institute of Oncology (EIO). Ann Oncol 2000; 11:301–306.

    Article  PubMed  CAS  Google Scholar 

  116. Roth AD, et al. 5FU as protracted continuous IV infusion (5Fupiv) can be added to full dose taxotere-cisplatin (TC) in advanced gastric carcinoma (AGO). Eur J Cancer 1999; 35:S130–S139.

    Article  Google Scholar 

  117. Vanhoefer U, et al. Phase n study of docetaxel as second line chemotherapy (CT) in metastatic gastric cancer. ASCO Proc 1999; 18:303a.

    Google Scholar 

  118. Andre T, et al. Docetaxel-epirubicine as second-line treatment for patients with advanced gastric cancer. ASCO Proc 1999; 18:277a.

    Google Scholar 

  119. CPT-11 Gastrointestinal Cancer Study Group, Futatsuki K, et al. Late phase n study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Gan To Kagaku Ryoho 1994; 21:1033–1038.

    PubMed  CAS  Google Scholar 

  120. Kohne CH, et al. Final results of a phase n trial of CPT-1 in patients with advanced gastric cancer. ASCO Proc 1999; 18:258a.

    Google Scholar 

  121. Shirao K, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15:921–927.

    PubMed  CAS  Google Scholar 

  122. Boku N, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17:319–323.

    PubMed  CAS  Google Scholar 

  123. Ajani JA, et al. Irinotecan plus cisplatin in advanced gastric or gastro-esophageal junction carcinoma. Oncology 2001; 15:52–54.

    PubMed  CAS  Google Scholar 

  124. Raymond E, Chaney SG, Taamma A, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9:1053–1071.

    Article  PubMed  CAS  Google Scholar 

  125. Kim DY, Kim JH, Lee SH, et al. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol 2003; 14:383–387.

    Article  PubMed  CAS  Google Scholar 

  126. Murray GI, et al. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998; 43:791–797.

    Article  PubMed  CAS  Google Scholar 

  127. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastro-esophageal junction. N Engl J Med 2001; 345:725–730.

    Article  PubMed  CAS  Google Scholar 

  128. The Gastrointestinal Tumor Study Group. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 1982; 49:1116–1122.

    Article  Google Scholar 

  129. Imanaga H, Nakazato H. Results of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J Surg 1977; 2:213–221.

    Article  PubMed  CAS  Google Scholar 

  130. Hermans J, et al. Adjuvant therapy after curative resection for gastric caner: meta-analysis of randomized trials. J Clin Oncol 1993; 11:1441–1447.

    PubMed  CAS  Google Scholar 

  131. Pignon JP, Ducreux M, Rougier P. Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. J Clin Oncol 1994; 12:877–878.

    PubMed  CAS  Google Scholar 

  132. Mari E, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’ Apparato Digerente). Ann Oncol 2000; 11:837–843.

    Article  PubMed  CAS  Google Scholar 

  133. Minsky BD. The role of radiation therapy in gastric cancer. Semin Oncol 1996; 23:390–396.

    PubMed  CAS  Google Scholar 

  134. Budach VG. The role of radiation therapy in the management of gastric cancer. Ann Oncol 1994; 5:37–48.

    PubMed  Google Scholar 

  135. Hallissey MT, et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: a 5 year follow-up. Lancet 1994; 343:1309–1312.

    Article  PubMed  CAS  Google Scholar 

  136. Abe M, et al. Clinical experiences with intraoperative radiotherapy of locally advanced cancers. Cancer 1980; 45:40–48.

    Article  PubMed  CAS  Google Scholar 

  137. Abe M, et al. Japan gastric trials in intraoperative radiation therapy. Int J Radiat Oncol Biol Phys 1988; 15:1431–1433.

    PubMed  CAS  Google Scholar 

  138. Abe M, et al. Intraoperative radiotherapy of gastric cancer. Cancer 1974; 34:2034–2041.

    Article  PubMed  CAS  Google Scholar 

  139. Pelton JJ, et al. The influence of surgical margins on advanced cancer treated with intraoperative radiation therapy (IORT) and surgical resection. J Surg Oncol 1993; 53:30–35.

    Article  PubMed  CAS  Google Scholar 

  140. Sindelar WF, et al. Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. Am J Surg 1993; 165:178–186.

    Article  PubMed  CAS  Google Scholar 

  141. Abe M, et al. Intraoperative radiotherapy in carcinoma of the stomach and pancreas. World J Surg 1987; 11:459–464.

    Article  PubMed  CAS  Google Scholar 

  142. Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993; 36:564–572.

    Article  PubMed  CAS  Google Scholar 

  143. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. New Engl J Med 1997; 336:980–987.

    Article  Google Scholar 

  144. Singletary Se. Current treatment options for inflammatory breast cancer. Ann Surg Oncol 1999; 6:228–229.

    Article  PubMed  CAS  Google Scholar 

  145. Provisor AJ, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 1997; 15:76–84.

    PubMed  CAS  Google Scholar 

  146. Martinez-Monge R, et al. Patterns of failure and long-term results in high-risk resected gastric cancer treated with post-operative radiotherapy with or without intraoperative electron boost. J Surg Oncol 1997; 66:24–29.

    Article  PubMed  CAS  Google Scholar 

  147. Kang YK, et al. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. ASCO Proc 1996; 15:210–215.

    Google Scholar 

  148. The Dutch Gastric Cancer Group (DGCD), Songun I, et al. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. Eur J Cancer 1999; 35:558–562.

    Article  PubMed  CAS  Google Scholar 

  149. Zhang ZX, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC): Report on 370 patients. Int J Radiat Oncol Biol Phys 1998; 42:929–934.

    Article  PubMed  CAS  Google Scholar 

  150. Shchepotin IB, et al. Intensive preoperative radiotherapy with local hyperthermia for the treatment of gastric carcinoma. Surg Oncol 1994; 3:37–44.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA

    Diane Hershock MD, PhD

Authors
  1. Diane Hershock MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oregon Health and Science University, Portland, OR

    Douglas O. Faigel MD, FACG, FASGE (Associate Professor of Medicine, Director of Endoscopy) (Associate Professor of Medicine, Director of Endoscopy)

  2. Hospital of the University of Pennsylvania, Philadelphia, PA

    Michael L. Kochman MD, FACP, FASGE (Professor of Medicine and Surgery, Co-Director Gastrointestinal Oncology) (Professor of Medicine and Surgery, Co-Director Gastrointestinal Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press, Totowa, NJ

About this chapter

Cite this chapter

Hershock, D. (2006). Medical and Surgical Therapy for Gastric Cancer. In: Faigel, D.O., Kochman, M.L. (eds) Endoscopic Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-172-7_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-172-7_16

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-532-3

  • Online ISBN: 978-1-59745-172-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation